Prevention of deep vein thrombosis in pre-trochanteric hip fracture
Phase 3
Recruiting
- Conditions
- Deep vein thrombosis.Acute embolism and thrombosis of deep veins of lower extremityI82.4
- Registration Number
- IRCT20190325043107N16
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Presence of peri-trochanteric femur fracture
Exclusion Criteria
Heparin sensitivity
Endocarditis
Liver disease
Hematologic diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Deep vein thrombosis. Timepoint: Once before the intervention and once at the end of the study (30 days later). Method of measurement: Take a blood test and check the level of D-Dimer in the blood.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of enoxaparin and rivaroxaban in preventing DVT in pre-trochanteric hip fracture patients?
How does oral rivaroxaban compare to enoxaparin in DVT prophylaxis efficacy for pre-trochanteric hip fractures?
Which biomarkers predict response to enoxaparin or rivaroxaban in DVT prevention for lower extremity thrombosis (I82.4)?
What adverse events are associated with enoxaparin versus rivaroxaban in orthopedic trauma patients?
Are there combination therapies with enoxaparin or rivaroxaban for DVT prophylaxis in hip fracture management?